Denosumab extends the pool of pharmacotherapy options for the management of skeletal involvement in patients with prostate cancer

Czech version

Authors: D. Pacík
Authors‘ workplace: Urologická klinika FN Brno
Published in: Urol List 2012; 10(2): 11-14

Overview

A high percentage of prostate cancer patients are at risk of skeletal involvement. Osteoporosis secondary to hormonal ablative therapy and skeletal adverse events as a result of metastatic bone involvement have a negative impact on the patients’ quality of life and their prognosis. Prevalence and delay of SRE must therefore be foregrounded. This article summarizes available evidence about fully-human monoclonal antibody denosumab. This agens has a novel mechanism of action, and thus extends the pool of medicaments influencing bone metabolism. This article is based on data from trials directly comparing denosumab and zoledronic acid, which represents current standard in the treatment of patients with prostate cancer with bone involvement.

Key words:
prostate cancer, denosumab, SRE, zoledronic acid, bone metastases, CTIBL

Sources

1. http://www.uroweb.cz/index.php?pg=dg--nadory-prostaty--epidemiologie-ceska-republika--vyvoj-incidence-mortalita

2. http://www.linkos.cz/informace-pro-praxi/zasady-cytostaticke-lecby.

3. Bolla M. Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol 1999; 35 (Suppl 1): S23–S26.

4. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360(9327): 103–108.

5. Messing EM, Manola J, Sarosdy M et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24): 1781–1788.

6. Maillefert JF, Sibilia J, Michel F et al. Bone mineral density in men treated with synthetic gonadotropinreleasing hormone agonists for prostatic carcinoma. J Urol 1999; 161(4): 1219–1222.

7. Shahinian VB, Kuo YF, Freeman JL et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005; 352(2): 154–164.

8. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005; 294(2): 238–244.

9. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies Cancer Treat Rev 2001; 27(3): 165–176.

10. Saad F, Lipton A, Cook R et al. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007; 110(8): 1860–1867.

11. Norgaard M, Jensen AO, Jacobsen JB et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184(1): 162–167.

12. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94(19): 1458–1468.

13. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411–422.

14. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23(22): 25–35.

15. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377(9768): 813–822.

16. Smith MR, Egerdie B, Toriz NH et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. N Engl J Med 2009; 361(8): 745–755.

17. Matoušková M, Hanuš M. Bisfosfonáty v léčbě kostních metstáz v urologii. Urologie pro praxi 2009; 10: 282–286.

18. Rosen LS, Gordon D, Tchekmedyian S et al. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with NSCLC and other solid tumors: a randomised, phase III, double blind, placebo controlled trial. Cancer 2004; 100(12): 2613–2621.

19. Brown J, Carducci M, Fizazi K et al. CIBD 2010: abstract 9 and oral presentation.

20. Lipton A, Siena S, Rader M et al. Comparison of denosumab versus zoledronic acid for treatment of bone metastases in advanced cancer patients: An integrated analysis of 3 pivotal trials European Cancer Organisation 2010: abstract 1249P and poster presentation.